Introduction {#s1}
============

Statins are the first-line lipid modifier for reducing cardiovascular morbidity and mortality ([@bib49]; [@bib37]). Statins have revolutionized the prevention and treatment of cardiovascular disease, and inspired the development of a range of effective interventions targeting the reduction of low-density lipoprotein (LDL)-cholesterol. Statins have long been suspected of having additional beneficial effects beyond lipid modulation ([@bib60]), such as on inflammation ([@bib60]), another potential target for reducing cardiovascular disease ([@bib1]). Meta-analysis of randomized controlled trials (RCTs) suggests statins are more effective at reducing mortality than proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors or ezetimibe ([@bib59]; [@bib31]). However, these findings may be more apparent than real, stemming from differences in trial design, such as shorter duration of the PCSK9 inhibitor trials ([@bib31]), the predominance of industry funded statin trials ([@bib26]) or the difficulty of interpreting trials of 'soft' events when the treatment affects diagnostically relevant criteria, that is lipid levels ([@bib69]). To investigate this anomaly, a previous study conducted a systematic agnostic scan of metabolic profile in a trial of statins compared to a PCSK9 inhibitor, which found few differences ([@bib73]). While characterization of the metabolic effects of statins suggested extensive effects on lipids and fatty acids ([@bib82]); these investigations were not able to include a factor which has previously been proposed as contributing to statin's effectiveness, that is effects on male hormones ([@bib61]), although questions have been raised as to whether statins are as effective in women as men ([@bib46]). However, meta-analysis of the available trial evidence suggests similar relative benefits of LDL-cholesterol reduction by statins for men and women ([@bib23]), although the trials mainly concern men (73.2%) which may preclude detection of important sex differences. Men are also at substantially higher risk than women ([@bib18]) giving larger absolute benefits in men than women at the same reduction in relative risk.

RCTs are not usually designed or powered to test mediating mechanisms. In addition, trials of statins on cardiovascular disease outcomes designed to be sex-specific are lacking. To assess a potential pathway by which statins might additionally operate, we used Mendelian randomization (MR), an observational study design that avoids confounding by taking advantage of the random allocation of genetic material at conception ([@bib74]), here specifically genetic variants mimicking effects of lipid modifiers. This random allocation at conception also avoids selection bias as long as few deaths have occurred between randomization and recruitment due to exposure, outcome, or other causes, that is competing risk, of the outcome ([@bib67]). So, here we focused on ischemic heart disease (IHD) ([@bib30]), using the UK Biobank ([@bib13]) to investigate whether testosterone mediated any of the effects of statins, PCSK9 inhibitors or ezetimibe on IHD in men or women using univariable and multivariable MR. As a further test, given some anti-inflammatories have also been shown to have opposite effects on male hormones compared to statins, specifically the interleukin one receptor antagonist (IL-1Ra), anakinra ([@bib16]), we assessed whether the genetic variants mimicking effects of anakinra or tocilizumab targeting the interleukin six receptor (IL-6r) had opposite patterns of effects on testosterone and IHD ([@bib1]; [@bib75]; [@bib27]) to statins. [Figure 1](#fig1){ref-type="fig"} illustrates the possible additional effects of statins, anakinra or tocilizumab on IHD via male hormones in the context of the well-established benefits of statins, PCSK9 inhibitors and ezetimibe acting via LDL-cholesterol and of anti-inflammatories in IHD.

![Directed acyclic graph showing the well-established protective effects of lipid modifiers and anti-inflammatories on IHD (solid lines) and possible additional pathways (dashed lines) investigated here.\
Green indicates a lowering effect, red indicates an increasing effect.](elife-58567-fig1){#fig1}

Results {#s2}
=======

The six single neucleotide polymorphisms (SNPs) mimicking effects of statin (rs12916, rs5909, rs10066707, rs17238484, rs2006760 and rs2303152 from *HMGCR*) ([@bib20]) were all correlated (r^2^ \>0.13). In the main analysis we used only the lead SNP, rs12916. Of the 7 SNPs mimicking effects of PCSK9 inhibitors (rs11206510, rs2149041, rs7552841, rs10888897, rs2479394, rs2479409 and rs562556 from *PCSK9*) ([@bib20]), the three independently (r^2^ \<0.05) and most strongly associated with LDL-cholesterol (rs11206510, rs2149041 and rs7552841) were used in the main analysis. Of the 5 SNPs mimicking effects of ezetimibe (rs10260606 (proxy of rs2073547, r^2^ = 0.99), rs2300414, rs10234070, rs7791240, rs217386 from *NCP1L1*) ([@bib20]), two SNPs (rs2300414 and rs10234070) were discarded because their F-statistic for LDL-cholesterol was \<10. The remaining three SNPs were all correlated at r^2^ \>0.05. rs2073547 was used in the main analysis because it had the strongest association with LDL-cholesterol. [Supplementary file 1a](#supp1){ref-type="supplementary-material"} shows the associations with LDL-cholesterol by sex for the independent SNPs used to mimic effects of statins, PCSK9 inhibitors and ezetimibe. [Supplementary file 1b](#supp1){ref-type="supplementary-material"} shows the associations of the two SNPs mimicking effects of the anti-inflammatory, anakinra, (rs6743376 and rs1542176 (r^2^ \<0.001)) with IL-1Ra and the associations of the SNP (rs7529229), mimicking effects of tocilizumab use, with IL-6r.

There were 179,918 men with 25,410 cases of IHD and 212,080 women with 12,511 cases of IHD in the UK Biobank.

Instrument strength {#s2-1}
-------------------

The F-statistics for SNPs used to genetically mimic the effects of statins, PCSK9 inhibitors and ezetimibe were all \>10 in men and women ([Supplementary file 1a](#supp1){ref-type="supplementary-material"}), as were the F-statistics for the SNPs used to mimic the effects of anakinra and tocilizumab ([Supplementary file 1b](#supp1){ref-type="supplementary-material"}). The F-statistics for the 125 and 254 SNPs predicting testosterone in men and women were all greater than 10, with mean 128.6 and 83.3, respectively.

Sex-specific associations of genetically mimicked lipid modifiers with testosterone {#s2-2}
-----------------------------------------------------------------------------------

Genetically mimicked effects of statins reduced testosterone in men but not women ([Table 1](#table1){ref-type="table"}). Genetically mimicked effects of PCSK9 inhibitors and of ezetimibe did not affect testosterone in men or women ([Table 1](#table1){ref-type="table"}). Findings were similar in sensitivity analysis including correlated SNPs, where available ([Table 1](#table1){ref-type="table"}). PCSK9 inhibitors and ezetimibe were not investigated further, given the lack of association with testosterone in men and women.

###### Sex-specific Mendelian randomization estimates (where possible) for effects of genetically mimicked statins, PCSK9 inhibitor and ezetimibe (in effect sizes of LDL-cholesterol) on testosterone (effect size) in men and women using the UK Biobank .

                                                            Mendelian Randomization estimates                             
  ------- ----------------- --- --------------------------- ----------------------------------- ---------------- -------- ---------------
  Men     Statin            1   Inverse variance weighted   −0.15                               −0.23 to −0.06   0.001    
          Statin            6   Inverse variance weighted   −0.15                               −0.23 to −0.07   0.0005   
          PCSK9 inhibitor   3   Inverse variance weighted   0.04                                −0.11 to 0.18    0.63     
          PCSK9 inhibitor   3   Weighted median             0.07                                −0.13 to 0.27    0.29     
          PCSK9 inhibitor   3   MR-Egger                    0.34                                0.09 to 0.60     0.01     −0.01 (0.01)
          PCSK9 inhibitor   7   Inverse variance weighted   0.05                                −0.05 to 0.15    0.29     
          ezetimibe         1   Inverse variance weighted   0.04                                −0.15 to 0.23    0.68     
          ezetimibe         3   Inverse variance weighted   0.05                                −0.12 to 0.22    0.55     
          ezetimibe         3   Weighted median             0.03                                −0.13 to 0.18    0.72     
          ezetimibe         3   MR-Egger                    0.24                                −0.52 to 1.0     0.54     −0.01 (0.52)
  Women   Statin            1   Inverse variance weighted   0.04                                −0.06 to 0.14    0.45     
          Statin            6   Inverse variance weighted   0.03                                −0.07 to 0.13    0.52     
          PCSK9 inhibitor   3   Inverse variance weighted   0.01                                −0.11 to 0.14    0.85     
          PCSK9 inhibitor   3   Weighted median             0.01                                −0.13 to 0.15    0.91     
          PCSK9 inhibitor   3   MR-Egger                    0.09                                −0.38 to 0.56    0.71     −0.003 (0.74)
          PCSK9 inhibitor   7   Inverse variance weighted   −0.004                              −0.14 to 0.13    0.95     
          ezetimibe         1   Inverse variance weighted   0.18                                −0.05 to 0.40    0.12     
          ezetimibe         3   Inverse variance weighted   0.12                                −0.08 to 0.31    0.24     

One statin SNP is rs12916, and six statin SNPs additionally included rs5909, rs10066707, rs17238484, rs2006760 and rs2303152 taking into account their correlations.

Three PCSK9 inhibitor SNPs are rs11206510, rs2149041 and rs7552841, and 7 PCSK9 inhibitor SNPs additionally included rs10888897, rs2479394, rs2479409 and, rs562556 taking into account all their correlations.

One ezetimibe SNP is rs2073547 (proxied by rs10260606), and three ezetimibe SNPs additionally included rs7791240 and rs217386 taking into account all their correlations.

The unit of LDL-cholesterol is approximately 0.83 mm/L. An effect size of testosterone is approximately, 0.23 nmol/L in women ([@bib24]) and 3.1 nmol/L in men ([@bib39]).

Sex-specific associations of genetically mimicked statin use and testosterone with IHD {#s2-3}
--------------------------------------------------------------------------------------

Genetically mimicked effects of statins reduced the risk of IHD in men and possibly women ([Table 2](#table2){ref-type="table"}) using IVW. Steiger filtering indicated directionality from testosterone to IHD in men and women. Genetically predicted testosterone was positively associated with IHD in men, but was not significantly associated with IHD in women, with similar estimates using IVW, the weighted median and MR-Egger. MR-Egger intercepts did not suggest the IVW estimates were invalid, but had wider confidence intervals ([Table 2](#table2){ref-type="table"}).

###### Mendelian randomization estimates for effects of genetically mimicked statins (effect sizes of LDL-cholesterol) and of genetically predicted testosterone (effect size) on IHD in men and women using the UK Biobank.

Table 2---source data 1.Genetic associations for men.

Table 2---source data 2.genetic associations for women.

                                                           Mendelian randomization estimates                          
  ------- -------------- ----- --------------------------- ----------------------------------- -------------- ------- ---------------
  Men     Statin mimic   1     Inverse variance weighted   0.55                                0.38 to 0.79   0.001   
          Statin mimic   6     Inverse variance weighted   0.54                                0.33 to 0.89   0.02    
          Testosterone   125   Inverse variance weighted   1.11                                1.04 to 1.19   0.003   
          Testosterone   125   Weighted median             1.18                                1.06 to 1.31   0.002   
          Testosterone   125   MR-Egger                    1.10                                0.98 to 1.23   0.09    0.01 (0.84)
  Women   Statin mimic   1     Inverse variance weighted   0.87                                0.59 to 1.27   0.46    
          Statin mimic   6     Inverse variance weighted   0.79                                0.54 to 1.13   0.20    
          Testosterone   254   Inverse variance weighted   0.96                                0.89 to 1.03   0.29    
          Testosterone   254   Weighted median             1.03                                0.92 to 1.14   0.63    
          Testosterone   254   MR-Egger                    1.08                                0.94 to 1.23   0.27    −0.004 (0.05)

One statin SNP is rs12916, and six statin SNPs additionally included rs5909, rs10066707, rs17238484, rs2006760 and rs2303152 taking into account all their correlations. The unit of LDL-cholesterol is approximately 0.83 mm/L. An effect size of testosterone is approximately, 0.23 nmol/L in women ([@bib24]) and 3.1 nmol/L in men ([@bib39]).

Considering genetically mimicked effects of statin together with genetically predicted testosterone, in men the multivariable estimates for genetically mimicked effects of statins on IHD allowing for testosterone we attenuated ([Table 3](#table3){ref-type="table"}) compared to the univariable estimates for effects of statins on IHD ([Table 2](#table2){ref-type="table"}). As a result, the multivariable MR-Egger estimates for genetically mimicked effects of statins on IHD, allowing for testosterone, were very similar for men and women (odds ratio 0.72, 95% confidence interval 0.57 to 0.90 for men and women meta-analyzed together). The multivariable associations of genetically predicted testosterone with IHD in men and women, allowing for genetically mimicked statins, ([Table 3](#table3){ref-type="table"}) were very similar to the respective univariable estimates for men and women ([Table 2](#table2){ref-type="table"}), but differed by sex (z-test p-value 0.01). The conditional F-statistics were 58.2 (men) and 68.5 (women) for testosterone and 3.5 (men) and 6.8 (women) for effects of genetically mimicked statins. The Q statistics for instrument validity were significant (212.5 in men and 323.1 in women), and the multivariable MR-Egger intercepts were significant in men and women, substantiating the use of the MR-Egger estimates.

###### Multivariable Mendelian randomization estimates for effects of genetically mimicked statins (effect sizes of LDL-cholesterol) and of testosterone (effect size) together on IHD in men and women using the UK Biobank.

                                                                                                       Mendelian randomization estimates                          
  ------- -------------- ---------------------------------- -------------- --------------------------- ----------------------------------- -------------- ------- -------
  Men     Statin mimic   1 Statin SNP on LDL-cholesterol    Testosterone   Inverse variance weighted   1.05                                0.74 to 1.47   0.79    
          Testosterone   125 SNPs on testosterone           statin         Inverse variance weighted   1.11                                1.04 to 1.20   0.003   
          Statin mimic   1 Statin SNP on LDL-cholesterol    Testosterone   MR-Egger                    0.73                                0.48 to 1.11   0.14    
          Testosterone   125 SNPs on testosterone           statin         MR-Egger                    1.09                                1.02 to 1.17   0.02    0.005
          Statin mimic   6 Statin SNPs on LDL-cholesterol   Testosterone   Inverse variance weighted   1.02                                0.72 to 1.43   0.91    
          Testosterone   125 SNPs on testosterone           statin         Inverse variance weighted   1.11                                1.04 to 1.20   0.003   
  Women   Statin mimic   1 Statin SNP on LDL-cholesterol    Testosterone   Inverse variance weighted   0.98                                0.75 to 1.16   0.53    
          Testosterone   254 SNPs on testosterone           statin         Inverse variance weighted   0.96                                0.90 to 1.04   0.33    
          Statin mimic   1 Statin SNP on LDL-cholesterol    Testosterone   MR-Egger                    0.72                                0.55 to 0.94   0.02    
          Testosterone   254 SNPs on testosterone           statin         MR-Egger                    0.96                                0.89 to 1.03   0.27    0.001
          Statin mimic   6 Statin SNPs on LDL-cholesterol   Testosterone   Inverse variance weighted   0.92                                0.74 to 1.16   0.49    
          Testosterone   254 SNPs on testosterone           statin         Inverse variance weighted   0.97                                0.90 to 1.04   0.36    

One statin SNP is rs12916, and six statin SNPs additionally included rs5909, rs10066707, rs17238484, rs2006760 and rs2303152 taking into account all their correlations. The unit of LDL-cholesterol is approximately 0.83 mm/L. An effect size of testosterone is approximately, 0.23 nmol/L in women ([@bib24]) and 3.1 nmol/L in men ([@bib39]).

Sex-specific associations of genetically mimicked Anakinra and tocilizumab with testosterone and IHD {#s2-4}
----------------------------------------------------------------------------------------------------

Genetically mimicked effects of anakinra increased both the risk of IHD and testosterone in men but not women ([Table 4](#table4){ref-type="table"}). Genetically mimicked effects of tocilizumab were not clearly associated with testosterone in men or women ([Table 4](#table4){ref-type="table"}), so were not investigated further. Investigation of whether testosterone mediates the genetically mimicked effect of anakinra on IHD was not possible because sex-specific genetic associations of testosterone SNPs with IL-1Ra from suitably large GWAS are not available.

###### Mendelian randomization inverse variance weighted estimates for genetically mimicked effects of the anti-inflammatory anakinra raising IL-1Ra (effect size) ([@bib75]) on testosterone (effect size) and ischemic heart disease and for genetically mimicked effects of tocilizumab raising serum IL-6r (ng/ml) ([@bib48]) on testosterone in men and women using the UK Biobank .

          Therapy       Target   Outcome        \# SNPs   Measure   Estimate   95% CI          p-value
  ------- ------------- -------- -------------- --------- --------- ---------- --------------- ---------
  Men     Anakinra      IL-1Ra   testosterone   2         beta      0.022      0.01 to 0.04    0.002
                                 IHD            2         OR        1.08       1.01 to 1.15    0.017
          Tocilizumab   IL-6r    testosterone   1         beta      0.003      −0.06 to 0.13   0.96
  Women   Anakinra      IL-1Ra   testosterone   2         beta      −0.01      −0.04 to 0.01   0.24
                                 IHD            2         OR        0.99       0.91 to 1.08    0.86
          Tocilizumab   IL-6r    testosterone   1         beta      0.002      −0.02 to 0.02   0.84

SNPs mimicking anakinra are rs6743376 and rs1542176.

The SNP mimicking tocilizumab is rs7529229.

An effect size of testosterone is approximately, 0.23 nmol/L in women ([@bib24]) and 3.1 nmol/L in men ([@bib39]).

Discussion {#s3}
==========

Consistent with meta-analysis of RCTs this study provides genetic evidence that statins reduce testosterone in men ([@bib61]), and adds by showing that statins could partially operate on IHD, in men only, by reducing testosterone, as previously hypothesized ([@bib61]; [@bib62]) while having similar protective effects in men and women independent of testosterone. Previous Mendelian randomization studies have shown lower testosterone associated with lower risk of IHD, particularly in men ([@bib65]; [@bib34]; [@bib38]). Conversely, consistent with an RCT ([@bib16]), this study also provides genetic validation that the anti-inflammatory anakinra, targeting IL-1Ra, increases testosterone in men, and is consistent with a previous Mendelian randomization study showing anakinra increases IHD ([@bib27]), but adds by showing why these associations might occur and that they may be specific to men.

A more marked association of testosterone with IHD in men than women ([Table 2](#table2){ref-type="table"}) is consistent with sex differences in biology, where testosterone is the main sex hormone in men and is much higher in men than in women. The associations of genetically mimicked effects of statins, PCSK9 inhibitors or ezetimibe on testosterone is consistent with the evidence available ([@bib61]; [@bib43]; [@bib32]) and their mechanisms of action. Specifically, statins inhibit cholesterol synthesis, while PCSK9 inhibitors enable greater clearance of cholesterol, through increasing LDL-receptors, while ezetimibe reduces uptake of dietary cholesterol ([@bib49]; [@bib37]). However, some cells, such as Leydig cells, use de novo cholesterol synthesis to generate steroids, which can be reduced by statins ([@bib71]). Concerns about statins compromising androgen production pre-date the marketing of statins ([@bib19]; [@bib35]). Beneficial immunosuppressive effects of androgens in rheumatoid arthritis have long been known ([@bib15]), making androgen reduction a plausible mode of action for therapies, such as anakinra, whose primary indication is rheumatoid arthritis.

These findings may seem counter-intuitive given the essential role of testosterone in masculinity and reproduction. However, in 2015 the Food and Drug Administration in the United States required labelling changes for all testosterone prescriptions to warn of the risk of heart attacks and stroke on testosterone, although no sufficiently large RCT of testosterone administration has been conducted to confirm these effects ([@bib42]). The Endocrine Society has also recommended caution in the use of testosterone ([@bib6]). Meta-analysis of RCTs suggests androgen deprivation therapy reduces all-cause mortality, but is too small to quantify effects on specific diseases beyond prostate cancer ([@bib40]). As such, our Mendelian randomization findings of the effects of testosterone have some consistency with the limited experimental evidence. In addition, our findings are consistent with well-established evolutionary biology theory, that is reproductive success may be at the expense of longevity, possibly in a sex-specific manner, impling that central drivers of the reproductive axis, as well as androgen production and catabolism, and their environmental cues may be relevant to IHD ([@bib63]; [@bib68]; [Figure 2](#fig2){ref-type="fig"}) encompassing the relations tested here ([Figure 1](#fig1){ref-type="fig"}). Notably, upregulation of indicators of plentiful living conditions, such as insulin, appear to cause IHD, particularly in men ([@bib84]), likely via gonadotropin releasing hormone (GnRH) ([@bib68]). Similarly, fatty acids may affect GnRH ([@bib78]; [@bib36]). In contrast, indicators of adversity, such as endotoxins promote an inflammatory response, involving interleukins, which suppresses the reproductive axis ([@bib28]) and thereby testosterone ([@bib79]), which may be reversed by anakinra possibly outweighing the benefits for IHD of suppressing inflammation ([@bib77]). Statins, in contrast reduce androgen production, while agents that suppress androgen catabolism, such as rofecoxib, have also had unexpectedly adverse effects on IHD ([@bib63]). Mechanisms by which androgens might cause IHD have not been extensively investigated, but likely involve coagulation and red blood cell attributes. Several haemostatic and thrombotic factors, such as thromboxane A~2~ ([@bib45]; [@bib2]), endothelin-1 ([@bib47]; [@bib80]; [@bib55]), nitric oxide ([@bib45]; [@bib53]) and possibly thrombin ([@bib44]; [@bib21]), may be driven by androgens and likely play a role in IHD ([@bib66]; [@bib83]; [@bib41]). Von Willebrand factor ([@bib56]) and asymmetric dimethylarginine ([@bib70]) are also modulated by statins and may cause IHD ([@bib1]; [@bib5]), whether they are driven by testosterone is unknown. Several red blood cell attributes are affected by androgens, from reticulocytes to hematocrit ([@bib22]; [@bib29]), but exactly which causes IHD is unclear, although reticulocytes are a possibility ([@bib4]). Currently, comprehensive genetic validation of these pathways is hampered by the lack of availability of large sex-specific genome wide association studies (GWAS) of cytokines and coagulation factors.

![Schematic diagram showing the well-established protective effects of lipid modifiers on IHD (solid green lines) in the context of additional relevant pathways (green protective, red harmful) from an evolutionary biology perspective.\
(Key: GnRH: gonadotropin releasing hormone, RBC: red blood cell, LDL: low density lipoprotein).](elife-58567-fig2){#fig2}

Despite providing information that may be relevant to the performance of statins, and to the development of other therapies to protect against cardiovascular disease ([@bib64]), some limitations of this study exist. First, valid instruments should fulfill three assumptions, that is relate strongly to the exposure, not be associated with potential confounders and satisfy the exclusion restriction assumption. The F-statistics were \>10. Despite high conditional F-statistics for testosterone the conditional F-statistics for the genetic mimics of statins were quite low and the Q-statistics for instrument validity were high suggesting pleiotropy, which we addressed by using multivariable MR-Egger. The associations with testosterone in women were not adjusted for factors, such as menopausal status, hormone use and history of oophorectomy, which could result in imprecision and weaker instruments. The SNPs used to mimic effects of statins, PCSK9 inhibitors and ezetimibe are well established ([@bib20]), and in genes that harbor the target of each lipid modifier (*HMGCR, PCSK9* and *NCP1L1* respectively). We did not include body mass index (BMI) as a risk factor explaining the effect of statins on IHD, because statins increase BMI ([@bib76]) and decrease the risk of IHD, so including them in the multivariable analysis may inflate the effect of mimicking statins on IHD, rather than explaining part of their effect on IHD. The SNPs mimicking effects of the anti-inflammatory anakinra have been validated as increasing IL-1Ra ([@bib27]), and the SNP used to mimic effects of tocilizumab is well-established as affecting IL-6r ([@bib75]). Testosterone's effects on IHD in men could be via adiposity, insulin or LDL-cholesterol rather than via testosterone. However, consistent with a previous MR study, we found testosterone did not affect BMI in men ([@bib17]), we also found little evidence that testosterone in men affected LDL-cholesterol (data not shown). We could not test whether testosterone in men affects insulin because of the lack of an insulin GWAS including the X chromosome. Sex-specific genetic associations were used throughout with exception of the genetic mimics of effects of anakinra and tocilizumab on IL1Ra and IL-6r respectively. However, inflammation operating on the reproductive axis would be expected to have sex-specific effects not sex-specific drivers. We selected between correlated SNPs based on p-values which is relatively arbitrary, and the estimates could be sensitive to the choice of SNPs. Repeating the analysis using a larger number of correlated SNPs, where possible, taking into account their correlation, gave a similar interpretation. MR studies can be confounded by population stratification. However, we used genetic associations from GWAS mainly comprising people of white British ancestry with genomic control. Functions of each SNP predicting the exposures are not all fully understood, so we cannot rule out the possibility that the SNPs are linked with IHD through other pathways although we used sensitivity analysis.

We used SNPs predicting testosterone, but not other exposures, obtained from the same study as the genetic effects on IHD. However given the estimates for testosterone were largely obtained from non-cases, the overlap unlikely introduced substantial bias ([@bib11]). Canalization, that is buffering of genetic factors during development, may occur however; whether it does so is unknown. Our findings, largely in Europeans, may not be applicable to other populations. However, causes are unlikely to act differently in different populations, although the causal mechanisms may not be as relevant in all settings ([@bib33]). The SNPs mimicking effects of statins, PCSK9 inhibitors and ezetimibe were previously selected for their relations with LDL-cholesterol and on functional grounds ([@bib20]), assuming the lipid modifiers act by action on lipids ([@bib20]), so it is possible that relevant SNPs might have been discarded if they work through other mechanisms independent of lipids. It is also possible that the SNPs mimicking lipid modifiers might act via a different lipid trait, such as apoB ([@bib51]). The SNPs mimicking effects of anakinra and tocilizumab were similarly selected. Replication based on genetic instruments functionally relevant to all the exposures would be ideal. However, we used the most recent, published genetic instruments for testosterone ([@bib54]). Replication based on another large sex-specific IHD GWAS where the IHD cases are not from the same study as the testosterone instruments, would be ideal. However, sex-specific summary statistics are not available for large existing IHD GWAS, such as CARDIoGRAM ([@bib41]). Moreover, the UK Biobank has the advantage of being very intensively genotyped and including the X chromosome, which is important for testosterone, but is not usually included in publicly available summary statistics. Lack of replication is a limitation of this study. Lastly, Mendelian randomization assesses the lifelong effects of an endogenous exposure rather than short-term effects of an interventions assessed in an RCT. Our estimates give an indication of the role of the exposures rather than the exact effects of the corresponding interventions. Nevertheless our estimates for statins on IHD are comparable with meta-analyses of statin trials considering similar outcomes ([@bib23]).

Here, we present a hypothesis driven study examining the role of testosterone in mediating the effect of specifically statins in IHD, particularly in men. Future work could encompass a comprehensive sex-specific multivariable MR to confirm the role of sex hormones and sex hormone binding globulin in IHD as well as any mediation of their effects by key lipids, such as LDL-cholesterol or apoB. This work would be facilitated by the development of published genetic instruments for estrogen in women. Future work could also encompass assessing whether any other drugs that reduce cardiovascular disease, such as canakinumab ([@bib52]), also impact testosterone.

Taken together these complimentary findings for statins and anakinra raise the possibility that modulating testosterone, by whatever means, is a relevant feature for modulating IHD in men, with potential relevance to the development of new interventions, side-effects of existing interventions, re-purposing and appropriate use. Statins lowering testosterone could also be relevant to the muscle weakness or pain experienced on statins ([@bib14]). Recognition that statins lower testosterone might also provide greater impetus for investigation of their role in other relevant conditions, such as prostate cancer ([@bib3]). Conversely, statins and anakinra did not clearly affect testosterone in women ([Table 1](#table1){ref-type="table"}) nor did testosterone mediate the effect of statins on IHD in women ([Table 3](#table3){ref-type="table"}). These differences by sex highlight the need for sex-specific approaches to IHD prevention and management, specifically in terms of the use of statins and investigation more broadly of causes of IHD.

Conclusion {#s3-1}
----------

Genetic variants mimicking effects of statins and anakinra had opposite effects on testosterone and IHD in men, consistent with the effects of statins on IHD in men being partially mediated by testosterone. This insight that the pleiotropic effects of statins could be mediated by testosterone in men has implications for the use of existing interventions to prevent and treat IHD, the development of new interventions for IHD and the re-use of statins for other androgen related conditions. Genetic confirmation that anakinra raises testosterone suggests its use in rheumatoid arthritis might have cardiovascular side-effects, particularly in men. It also highlights the importance of considering whether vulnerability to major diseases and interventions to promote lifespan need to be sex-specific.

Materials and methods {#s4}
=====================

Genetic predictors mimicking effects of lipid and interleukin modifiers {#s4-1}
-----------------------------------------------------------------------

Established genetic variants mimicking effects of statins, PCSK9 inhibitors and ezetimibe were taken from published sources ([@bib20]) which selected SNPs from genes encoding proteins of the targets of each lipid modifier (*HMGCR* for statins, *PCSK9* for PCSK9 inhibitors and *NCP1L1* for ezetimibe) that lowered LDL-cholesterol. Genetic effects mimicking statins, PCSK9 inhibitors and ezetimibe were expressed in sex-specific effect sizes of LDL-cholesterol reduction taken from the largest available sex-specific GWAS summary statistics, that is the UK Biobank (<http://www.nealelab.is/uk-biobank>). The study was restricted to people of white British ancestry adjusted for the first 20 principal components, age, and age^2^. In the main analysis for each lipid modifier, we only used independent (r^2^ \<0.05) SNPs most strongly associated with LDL-cholesterol. We obtained correlations between SNPs for each lipid modifier based on the 1000 Genomes catalog from LDlink (<https://ldlink.nci.nih.gov>). In sensitivity analysis, we used all the relevant SNPs for each lipid modifier, along with a matrix of their correlations. Established genetic variants mimicking effects of anakinra and tocilizumab and their effects on IL-1Ra and IL-6r respectively were also taken from published sources ([@bib75]; [@bib48]).

Sex-specific genetic predictors of testosterone {#s4-2}
-----------------------------------------------

Strong (p-value\<5 × 10^−8^), independent (r^2^ \<0.05), sex-specific genetic predictors of testosterone were extracted from a published genome wide association study (GWAS) based on the UK Biobank and replicated in three independent studies (CHARGE Consortium, Twins UK and EPIC-Norfolk) ([@bib54]; [@bib72]). Genetic associations with testosterone in this study were adjusted for genotyping chip/release of genetic data, age at baseline, fasting time and ten genetically derived principal components ([@bib54]). We used all 125 genetic variants given for bioavailable testosterone, hereafter testosterone, in men and all 254 genetic variants given for testosterone in women, as previously ([@bib85]), because these had little correlation with sex hormone binding globulin (0.05 in men and 0.06 in women) ([@bib54]).

Sex-specific genetic associations with IHD {#s4-3}
------------------------------------------

Sex-specific genetic associations with IHD were taken from the UK Biobank individual data after excluding those with inconsistent self-reported and genotyped sex, excess relatedness (more than 10 putative third-degree relatives), abnormal sex chromosomes (such as XXY), or poor-quality genotyping (heterozygosity or missing rate \>1.5%). The sex-specific associations with IHD obtained using logistic regression were adjusted for the first 20 principal components, age, and assay array. IHD was based on self-report at baseline, subsequent hospitalization diagnoses (primary or secondary) of International Classification of Diseases (ICD) 9 410--4 or ICD10 I20-5 and death registration causes (primary or secondary) of ICD10 I20-5 up until December 2019.

Statistical analysis {#s4-4}
--------------------

The F-statistic was used to assess instrument strength, obtained using an approximation (mean of square of SNP-exposure association divided by square of its standard error) ([@bib8]). A conventional threshold for the F-statistic is 10. SNPs with an F-statistic \<10 were dropped.

Steiger filtering was used to check the directionality between testosterone and IHD. ([@bib25]) Sex-specific estimates of the associations of genetically predicted exposures (i.e., genetically mimicked effects of statins, PCSK9 inhibitors, ezetimibe, anakinra and tocilizumab) with testosterone and IHD, as well as estimates of the associations of genetically predicted testosterone with IHD were obtained by combining SNP-specific Wald estimates (SNP on outcome divided by SNP on exposure) using inverse variance weighting (IVW) with multiplicative random effects ([@bib10]). Multivariable MR was used to assess sex-specific associations of genetically predicted exposures with IHD allowing for testosterone, accounting for correlations between SNPs on the same chromosome obtained from LDlink. In the multivariable MR, we pooled the genetic instruments mimicking statins and the genetic instruments for testosterone together, extracted their associations with LDL-cholesterol and testosterone and fitted one multivariable model. We estimated the Sanderson-Windmejier multivariable conditional F-statistic ([@bib58]) to obtain a lower bound of the strength for each instrument conditional on the other exposure, and the Q statistics to asses pleiotropy, using the WSpiller/MVMR package ([@bib57]). Given this analysis is multivariable by design with few genetic variants available to mimic the effects of statins, we used the multivariable MR-Egger estimates ([@bib50]).

Sensitivity analysis {#s4-5}
--------------------

Where possible we used methods with different assumptions to assess the validity of the univariable MR estimates from IVW, which assumes balanced pleiotropy. MR-Egger is valid as long as the instrument strength independent of direct effect assumption holds ([@bib7]). We also used a weighted median which gives valid estimates when more than 50% of information comes from valid SNPs ([@bib9]). However, for exposures instrumented by correlated SNPs we did not give the weighted median or MR-Egger estimates because of concerns about their interpretability ([@bib12]).

Given this is a hypothesis driven study, with a positive control, we used a statistical significance level of 0.05. All statistical analysis was conducted using R version 3.6.1 (The R Foundation for Statistical Computing, Vienna, Austria). The MendelianRandomization R package was used for the MR estimates. Estimates of genetic associations were taken from publicly available UK Biobank summary statistics, except the associations with IHD which were based on individual level genetic associations from the UK Biobank obtained under application \#42468. All UK Biobank data were collected with fully informed consent.

**Funding:** This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
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Additional files {#s6}
================

###### Associations of SNPs mimicking effects of lipid modifiers with LDL-cholesterol.

\(a\) SNP-specific estimates for SNPs mimicking effects of statins, PCSK9 inhibitor and ezetimibe on LDL-cholesterol (effect size) in women and men from the UK Biobank, and for comparison estimates for both sexes together from the *Global Lipids* Genetics *Consortium* (GLGC) ([@bib81]). (b) SNP-specific estimates for anakinra and tocilizumab SNPs on IL1-Ra ([@bib27]) and IL-6 ([@bib75]) respectively.

Data availability {#s7}
=================

All data generated or analysed during this study are included in the manuscript and supporting files.
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**Acceptance summary:**

The authors performed a Mendelian randomization analysis of statin, PCSK9 inhibitor and ezetimibe use on ischemic heart disease to address a clinically relevant question -- could the apparent additional benefits of statins and other similar treatments, over and above lowering lipids, be mediated by favourable effects on testosterone levels? They found a potentially interesting link between statins and testosterone -- genetic variants in the gene encoding the HMGcoR receptor that are known to alter LDL-cholesterol levels.

**Decision letter after peer review:**

Thank you for submitting your article \"Pleiotropic effects of statins on ischemic heart disease: a Mendelian Randomization study in the UK Biobank\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Matthias Barton as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Timothy Frayling (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, when editors judge that a submitted work as a whole belongs in *eLife* but that some conclusions require a modest amount of additional new data, as they do with your paper, we are asking that the manuscript be revised to either limit claims to those supported by data in hand, or to explicitly state that the relevant conclusions require additional supporting data.

Our expectation is that the authors will eventually carry out the additional experiments and report on how they affect the relevant conclusions either in a preprint on bioRxiv or medRxiv, or if appropriate, as a Research Advance in *eLife*, either of which would be linked to the original paper.

Title: Please modify the title to comply with *eLife* requirements. The title should not exceed 120 characters. Two part titles containing a colon punctuation mark (\":\") are not allowed.

Summary:

This is a neat study using genetics to ask a clinically relevant question -- could the apparent additional benefits of statins and other similar treatments, over and above lowering lipids, be mediated by favourable effects on testosterone levels? The question becomes a little more complicated in that higher levels of testosterone tend to be beneficial for men\'s metabolic health but adverse for women and so the authors have used UK Biobank data, where it is easy to stratify analyses by sex.

The authors performed a Mendelian randomization (MR) analysis of statin, PCSK9 inhibitor and ezetimibe use on ischemic heart disease (IHD), and if these effects were mediated by testosterone in men or women using univariable and multivariable MR.

They have found a potentially interesting link between statins and testosterone -- genetic variants in the gene encoding the HMGcoR receptor that are known to alter LDL-cholesterol levels (And so we know they are very good mimics for the on target effects of statins) and testosterone levels in men. The direction is that the alleles associated with lower LDL-cholesterol and therefore mimic statins also lower testosterone. There were no links for the other genes encoding the other targets of lipid lowering therapy. In addition, they assessed whether the genetic variants corresponding to anti-inflammatory effects of anakinra or tocilizumab use had effects on testosterone and IHD. The topic is very interesting.

Revisions for this paper:

1\) The main finding is that, when adjusting for testosterone levels, the protective benefit of statins via the HMGcoR on heart disease attenuates from 0.54 odds ratio to 0.73 in men (when using the MR egger approach. There are wide 95% CIs around these estimates but the results imply that the testosterone effect is similar to the lowering LDL-cholesterol effect, which is extremely counter intuitive given that we know about LDL-cholesterol and heart disease. The reliance on a sensitivity analysis -- MR egger -- when the main analysis showed evidence of pleiotropy means the results could be very sensitive to slight differences in the parameters used. (SNPs and models).

2\) A second concern is that the genetic variants in HMGCoR are associated with BMI and adiposity (see Swerdlow et al. Lancet publication using the HMGcoR SNPs to show an association with diabetes) whereas the others are less so. The authors need to assess the potential for the effect being mediated via BMI/adiposity rather than testosterone. Such a mechanism would be consistent with sex differences because women are at lower risk of heart disease than men for a given BMI. Likewise, many of the testosterone SNPs are highly pleiotropic, with many primarily associated with adiposity and insulin resistance and lipid levels. My concern is that the pleiotropy will lead to false inferences. The authors have partially addressed this with some approaches such as MR-Egger, but these are not infallible. The multivariable MR needs to include the adiposity measures. multivariable MR with adiposity measures, steiger filtering of SNPs that have larger effects on metabolic potentially mediating traits than they do on lipids or testosterone could be alternative approaches to try.

3\) It would be relevant to see the results replicated in a two sample MR setting where the IHD cases are not from the same dataset as the testosterone and LDL SNPs. The heart disease GWAS consortia have not analysed separately by sex, which makes this very difficult, but there may be other large studies where this is possible ? If this cannot be done readily it should be discussed and noted as a limitation.

4\) All of this means that the conclusion that \"statins partially operate on IHD by reducing testosterone in men\" is likely overstated.

5\) A further major concern is the selection of SNPs in vicinity of the *HMGCR*, *NCP1L1* and *PCSK9* genes as instruments for the statin, PCSK9 and ezetimibe use, respectively. For example, a lookup of the instrument included for ezetimibe use (rs10260606) in the publicly available sex-combined GWAS on ezetimibe treatment (http://www.nealelab.is/uk-biobank) resulted in an association p-value of 0.02 being a rather weak instrument. Also in the referenced publication of Ference et al., 2019, that was used as basis for the instrument selection, these SNPs were (to my understanding) selected to assess potential drug targets, and not to reflect medication use.

6\) Which statistical model was used to calculate the sex-specific genetic associations with IHD (I assume logistic regression)? Please provide the number of cases and controls per sex-stratum that were finally included in this association analysis also in the main text (not only in the Abstract).

Please provide the p-value level that was applied to declare significance of the results.

7\) By conducting a sex-stratified analyses, have the authors considered the impact of collider bias. As if the genetic instruments are associated with sex and the outcome measures are also associated with sex, by stratifying based on a common cause of the exposure and outcome, a distorted/erroneous association may occur.

8\) Please give more details about multivariate MR analysis. E.g. did you pool the genetic proxies for statin and testosterone all together and then extracted the associations of all these SNPs with LDL-cholesterol and testosterone and fitted it in one model?

Revisions expected in follow-up work:

1\) As the authors aim to investigate sex-specific benefits of statin therapies, why only focus on testosterone. I think you should also look at 17β-oestradiol and SHBG (both available in UKBB), and conduct a multivariate MR to determine which would be the independent causal factor for IHD among the three (e.g. PMID: 32203549) and then forward the independent hormones/proteins in a multivariate model with LDL-cholesterol or apoB (drug targets of lipid lowering drugs) to determine whether these hormones would exert independent roles in contributing to IHD beyond the lipids. If this is the case, then it makes sense to further determine whether the genetic instruments of the drug targets show a sex-specific association with the sex hormones. This issue could be addressed in the Discussion.

10.7554/eLife.58567.sa2

Author response

> Revisions for this paper:
>
> 1\) The main finding is that, when adjusting for testosterone levels, the protective benefit of statins via the HMGcoR on heart disease attenuates from 0.54 odds ratio to 0.73 in men (when using the MR egger approach. There are wide 95% CIs around these estimates but the results imply that the testosterone effect is similar to the lowering LDL-cholesterol effect, which is extremely counter intuitive given that we know about LDL-cholesterol and heart disease. The reliance on a sensitivity analysis -- MR egger -- when the main analysis showed evidence of pleiotropy means the results could be very sensitive to slight differences in the parameters used. (SNPs and models).

Please accept our apologies for a counter-intuitive finding. We are in no way trying to question the role of LDL-cholesterol in heart disease. We are instead trying to address two important health issues. First, the higher rates of heart disease in men than women,^1^ which are a factor contributing to shorter life expectancy in men than women. Second, the apparent pleiotropic effects of statins, because their explication might facilitate the discovery of much needed new treatments for cardiovascular disease.

As regards, the size of the estimates for statins via HMGcoR on ischemic heart disease (IHD). After allowing for testosterone, the estimates in men changed from being larger than the estimates in women to being very similar to the estimates in women, as expected. However, we agree that the magnitude of the estimates in Mendelian randomization (MR) is difficult to interpret because MR estimates capture lifetime effects rather than a possibly short-term exposure. We have clarified this important point to the Discussion, by making the following change:

From: "Lastly, Mendelian randomization assesses the lifelong effects of an endogenous exposure rather than short-term effects of an interventions assessed in an RCT, nevertheless our estimates for statins on IHD are comparable with meta-analyses of statin trials considering similar outcomes.^2^"

To: "Lastly, Mendelian randomization assesses the lifelong effects of an endogenous exposure rather than short-term effects of an interventions assessed in an RCT. Our estimates give an indication of the role of the exposures rather than the exact effects of the corresponding interventions. Nevertheless, our estimates for genetically mimicked statins on IHD are comparable with meta-analyses of statin trials considering similar outcomes.^2^ "

Please accept our apologies for being unclear about the use of the MR-Egger estimate. For univariable mendelian randomization (MR), MR-Egger is a sensitivity analysis. For the multivariable MR, when the analysis is multivariable by design with few genetic variants specifically predicting the exposures, as here for statins, then the MR-Egger estimate is most likely to be reliable.^3^ It is also recommended to use the MR-Egger multivariable estimate when the multivariable MR-Egger intercept is significant,^3^ as here. We have added this point to the Materials and methods:

"Given this analysis is multivariable by design with few genetic variants available to mimic the effects of statins, we used the multivariable MR-Egger estimates^3^."

We also amended the Results to be clearer by making the following change:

From: "Correspondingly, the multivariable MR-Egger intercepts were significant in men and women, so we used the MR-Egger estimates ^3^."

To: "Correspondingly, the multivariable MR-Egger intercepts were significant in men and women."

> 2\) A second concern is that the genetic variants in HMGCoR are associated with BMI and adiposity (see Swerdlow et al. Lancet publication using the HMGcoR SNPs to show an association with diabetes) whereas the others are less so. The authors need to assess the potential for the effect being mediated via BMI/adiposity rather than testosterone. Such a mechanism would be consistent with sex differences because women are at lower risk of heart disease than men for a given BMI. Likewise, many of the testosterone SNPs are highly pleiotropic, with many primarily associated with adiposity and insulin resistance and lipid levels. My concern is that the pleiotropy will lead to false inferences. The authors have partially addressed this with some approaches such as MR-Egger, but these are not infallible. The multivariable MR needs to include the adiposity measures. multivariable MR with adiposity measures, steiger filtering of SNPs that have larger effects on metabolic potentially mediating traits than they do on lipids or testosterone could be alternative approaches to try.

Thank you very much indeed for raising these concerns as to whether the pleiotropic effects of statins are via BMI rather than testosterone. We have considered this possibility in detail.

First, we checked, as expected from Swerdlow,^4^ that statins increase BMI in men and women (beta 0.33 effect size, 95% confidence interval (CI) 0.20 to 0.47, in men and 0.31, 95% CI 0.22 to 0.40, in women, Author response table 1 below), using published instruments for BMI^5^ and rs12916-T to mimic effects of statins, and the UK Biobank sex-specific genetic associations with BMI (http://www.nealelab.is/uk-biobank).

Second, we considered the effect of BMI^5^ and genetically mimicked statins on IHD in univariable and multivariable MR. In univariable MR, as expected, BMI increased IHD (odds ratio (OR) 1.33, 95% confidence interval (CI) 1.15 to 1.55, in men and OR 1.23, 95% CI 1.02 to 1.48, in women) and genetically mimicked statins decreased IHD (OR 0.54, 95% CI 0.38 to 0.79 in men and had an estimate in the same direction in women OR 0.87, 95% CI 0.59 to 1.27, Author response table 1). In multivariable MR, considering the effects of BMI and genetically mimicked statins (rs12916-T) together on IHD, BMI had very similar associations with IHD as in the univariable analysis (OR 1.35, 95% CI 1.15 to 1.57 in men and women OR 1.27, 95% CI 1.07 to 1.52). In contrast, in the multivariable analysis including BMI genetically mimicked statins had a larger decreasing effect on IHD (OR 0.46, 95% CI 0.35 to 0.65 in men and OR 0.68, 95% CI 0.53 to 0.86 in women). As such, the protective effect of statins on IHD was increased by additionally considering BMI, so statins protective effect on IHD does not appear to be explained away by statins increasing BMI, in fact including BMI makes the protective effects of statins on IHD more marked. The multivariable MR is probably giving a larger effect size for statins than the univariable MR because it is showing the effects of "statins" after removing the harmful aspect driven by raising BMI. As such, statins raising BMI is unlikely to be a pathway by which statins protect against IHD, and we did not consider it further in the multivariable MR to keep the paper as simple and focused as possible. We have added this point in the Discussion as follows:

"We did not include body mass index (BMI) as a risk factor explaining the effect of mimicking statins on IHD, because statins increase BMI^4^ and decrease the risk of IHD, so including them in the multivariable analysis may inflate the effect of mimicking statins on IHD, rather than explaining part of the effect".

We agree that the testosterone SNPs may have pleiotropic effects possibly acting via adiposity, insulin resistance or lipids. Downstream effects of the exposures help explain how the exposure affects the outcome. Downstream effects of the exposures generate vertical pleiotropy which does not bias MR estimates, because it is a pathway through the exposure, rather than the genetic instrument operating by a pathway distinct from the exposure. Pleiotropy biases MR estimates, when it is horizontal pleiotropy, and the genetic instrument affects the outcome by a pathway distinct from the exposure. We also checked whether the testosterone SNPs operated via adiposity or lipids. The testosterone SNPs did not affect BMI in men, consistent with a previous Mendelian randomization study,^6^ as given below (Author response table 2). In contrast testosterone raised BMI in women and reduced LDL-cholesterol, however, testosterone in women does not affect IHD. We have added that these points in the Discussion.

"Testosterone's effects on IHD in men could be via adiposity, insulin or LDL-cholesterol rather than via testosterone. \[...\] We could not test whether testosterone in men affects insulin because of the lack of an insulin GWAS including the X chromosome."

Author response table 1: Univariable Mendelian randomization estimates for genetically mimicked statins (rs21916-T) and genetically predicted BMI (95 variants\*) on IHD in men and women in the UK Biobank.

\*after removing one variant predicting BMI (rs2112347) that was correlated with rs12916

Author response table 2: Univariable sex-specific Mendelian randomization estimates for testosterone on body mass index and LDL-cholesterol in men and women in the UK Biobank.

As suggested, we used Steiger filtering to check the direction from testosterone to IHD,^7^ which confirmed that the direction of causality was from testosterone to IHD in men and women. We have added this point in the Materials and methods and the Results.

In the Materials and methods:

"Steiger filtering was used to check the directionality between testosterone and IHD.^7^"

In the Results;

"Steiger filtering indicated directionality from testosterone to IHD in men and women."

> 3\) It would be relevant to see the results replicated in a two sample MR setting where the IHD cases are not from the same dataset as the testosterone and LDL SNPs. The heart disease GWAS consortia have not analysed separately by sex, which makes this very difficult, but there may be other large studies where this is possible ? If this cannot be done readily it should be discussed and noted as a limitation.

Please accept our apologies for being unclear. The testosterone SNPs were derived from the UK Biobank, but were also replicated in three independent studies,^8^ so they do have some replication. The LDL SNPs for statins, PCSK9 inhibitors and ezetimibe do not come from the same dataset as the IHD cases. The LDL SNPs come from Ference et al., as used previously to mimic the effects of lipid modifiers^9^. Only the beta co-efficients for the LDL SNPs on LDL come from the same study as the IHD cases. The beta coefficients are simply scaling factors which are quite similar to those from the Global Lipids Genetic consortium (GLGC), as we show in Supplementary file 1. We have added a column to that table to make it clearer. However, the GLGC does not have sex-specific genetic associations with LDL-c, so we used UK Biobank which gives sex-specific effect of the SNPs mimicking statins on LDL-c. We have explained this point, as given below:

"Strong (p-value\<5×10^-8^), independent (r^2^\<0.05), sex-specific genetic predictors of testosterone were extracted from a published genome wide association study (GWAS) based on the UK Biobank and replicated in three independent studies (CHARGE Consortium, Twins UK and EPIC-Norfolk) ^10\ 11^."

"Genetic effects mimicking statins, PCSK9 inhibitors and ezetimibe were expressed in sex-specific effect sizes of LDL-cholesterol reduction taken from the largest available sex-specific GWAS summary statistics, i.e., the UK Biobank (http://www.nealelab.is/uk-biobank)."

Thank you for this suggestion about replication, we would be very keen to do so. We cannot identify any other sex-specific GWAS of IHD. Most GWAS of IHD are composed largely of men, so one option would be to repeat the analysis using an IHD GWAS of mainly men. However, there are two issues with that approach. First a GWAS of mainly men does not provide replication by sex. Second, almost all previous GWAS are autosomal, so we are missing key items in the testosterone instrument from the X chromosome, which means this is not a true replication. We have clarified this point in the Discussion, by making the following change:

From: "Replication based on another large IHD GWAS, such as CARDIoGRAM^12^, would be ideal, but it is less intensively genotyped than the UK Biobank and excludes the X chromosome, making it unsuitable."

To: "Replication based on another large sex-specific IHD GWAS where the IHD cases are not from the same study as the testosterone instruments, would be ideal. However, sex-specific summary statistics are not available for large existing IHD GWAS, such as CARDIoGRAM.^12^ Moreover, the UK Biobank has the advantage of being very intensively genotyped and including the X chromosome, which is important for testosterone, but is not usually included in publicly available summary statistics. Lack of replication is a limitation of this study."

> 4\) All of this means that the conclusion that \"statins partially operate on IHD by reducing testosterone in men\" is likely overstated.

We fully accept that no study is ever definitive, so we have amended this sentence to say

"statins could partially operate on IHD by reducing testosterone in men\".

> 5\) A further major concern is the selection of SNPs in vicinity of the HMGCR, NCP1L1 and PCSK9 genes as instruments for the statin, PCSK9 and ezetimibe use, respectively. For example, a lookup of the instrument included for ezetimibe use (rs10260606) in the publicly available sex-combined GWAS on ezetimibe treatment (http://www.nealelab.is/uk-biobank) resulted in an association p-value of 0.02 being a rather weak instrument.

Thank you for these comments. Please accept our apologies for being unclear, we did not obtain the instruments for statins, PCSK9 or ezetimibe use from the UK Biobank GWAS of self-reports of drug use. There were three reasons for this choice. First, for comparability with other studies we used instruments from a previous study.^9^ Second, self-reports are not always very reliable, so a GWAS based on self-reports may generate instruments that represent noise rather than signal. This may be why MR studies exploring the effects of medications usually use genetic predictors related to the drug target, based on biological pathways so as to minimise potential bias. Third, the SNPs for statins, PCSK9 or ezetimibe are to some extent selected on functional rather than statistical grounds from relevant genes which encode proteins targeted by these drugs. This approach has the advantage of being functionally relevant, and so hopefully is relevant to the drugs biological effect, and shows the effect of the drug. The SNPs we used all had F-statistics greater than 10. On reflection, we realize that the language used to describe exposure was unclear as "effects of statin use" and we have amended it throughout, from "effects of statin use", to "mimic the effect of statins" or similar. Thank you for pointing this out.

> Also in the referenced publication of Ference et al., 2019, that was used as basis for the instrument selection, these SNPs were (to my understanding) selected to assess potential drug targets, and not to reflect medication use.

Thank you for these comments. As noted in the previous comment, we found it very tricky to find exactly the right words to describe the instruments for statins, PCSK9 inhibitors and ezetimibe clearly. We have carefully reviewed the underlying publications to find more appropriate wording to describe use of these variants in similar situations. As given below the original publications use the words "mimic the effect of \[the drug\] or "as a proxy for \[drug\] treatment".

Ference et al., 2019, used the wording "Genetic variants that mimic the effect of ...statins"^9^.

Ference et al., 2016, used the wording "We constructed genetic scores that mimic the effect of PCSK9 inhibitors and the effect of statins"^13^.

Ference et al., 2015, used the wording "To compare the biological effect of lower LDL-cholesterol mediated by inhibition of *NCP1L1*, *HMGCR*, or both on the risk of CHD, and to provide a context for interpreting the results of IMPROVE-IT, we sought to compare the effect of naturally random allocation to lower LDL-cholesterol on the risk of CHD mediated by genetic polymorphisms in the NPC1L1 gene (as a proxy for ezetimibe treatment), the *HMGCR* gene (as a proxy for statin treatment)".

We have amended the paper throughout to be consistent with the previous usage and to use the expression "mimic the effect of" or similar throughout.

> 6\) Which statistical model was used to calculate the sex-specific genetic associations with IHD (I assume logistic regression)? Please provide the number of cases and controls per sex-stratum that were finally included in this association analysis also in the main text (not only in the Abstract).

Thank you for pointing out this oversight, we have added that the associations with IHD were "obtained using logistic regression". Information about the number of cases is given in the main text.

> Please provide the p-value level that was applied to declare significance of the results.

We have added this point in the text:

"Given this is a hypothesis driven study, with a positive control, we used a statistical significance level of 0.05."

> 7\) By conducting a sex-stratified analyses, have the authors considered the impact of collider bias. As if the genetic instruments are associated with sex and the outcome measures are also associated with sex, by stratifying based on a common cause of the exposure and outcome, a distorted/erroneous association may occur.

Thank you very much indeed for raising the issue of collider bias. Stratifying on a common cause of exposure and outcome is typically used to address confounding, i.e., it removes bias rather than adds bias.^14^ Collider bias (or selection bias) typically occurs if there is selection (or stratification) on a common effect of the exposure and outcome,^14^ i.e., here the genetic variants and IHD. We do not think that sex is a result of the genetic variants or of IHD and hence collider bias is very unlikely upon stratification by sex.

> 8\) Please give more details about multivariate MR analysis. E.g. did you pool the genetic proxies for statin and testosterone all together and then extracted the associations of all these SNPs with LDL-cholesterol and testosterone and fitted it in one model?

Please accept our apologies for not explaining these points clearly. This is exactly the process we carried out. We have added this point, as follows:

"In the multivariable MR, we pooled the genetic instruments mimicking statins and the genetic instruments for testosterone together, extracted their associations with LDL-cholesterol and testosterone and fitted one multivariable model."

> Revisions expected in follow-up work:
>
> 1\) As the authors aim to investigate sex-specific benefits of statin therapies, why only focus on testosterone. I think you should also look at 17β-oestradiol and SHBG (both available in UKBB), and conduct a multivariate MR to determine which would be the independent causal factor for IHD among the three (e.g. PMID: 32203549) and then forward the independent hormones/proteins in a multivariate model with LDL-cholesterol or apoB (drug targets of lipid lowering drugs) to determine whether these hormones would exert independent roles in contributing to IHD beyond the lipids. If this is the case, then it makes sense to further determine whether the genetic instruments of the drug targets show a sex-specific association with the sex hormones. This issue could be addressed in the Discussion.

Thank you very much indeed for asking why we focused on testosterone. We have for many years been examining the theory that statins operate specifically by testosterone,^15\ 16^ as presented explicitly in Figure 1 of the paper. In contrast, we have not been investigating the role of estrogen in IHD. Large randomized controlled trials have shown that hormone replacement therapy in women does not protect against IHD,^17^ and estrogen does not protect against IHD in men.^18^ Nevertheless, the possibility of a role of estrogen in IHD remains, because hormone replacement therapy may differ from naturally occurring estrogen in women and in men the Coronary Drug project estrogen arms were stopped early. Sex hormone binding globulin (SHBG) could be an independent influence on IHD or an important moderator of the role of testosterone, which deserves investigation. However, as shown in Author response table 3 (below) estrogen and SHBG do not seem relevant to specifically the effects of statins on IHD in men.

Author response table 3: Mendelian randomization estimates for effects of genetically mimicked statins (per effect sizes of LDL-cholesterol) on estrogen and SHBG in men and women from the UK Biobank summary statistics (<http://www.nealelab.is/uk-biobank>).

The unit of LDL-cholesterol is approximately 0.83mm/L.

We agree completely that it is a very important question to assess the independent role of testosterone, 17β-oestradiol and SHBG in IHD by sex and the extent to which they operate via LDL-cholesterol or apoB. Currently there is a dearth of comprehensive genetic instruments for estrogen. Ruth et al., by far the largest GWAS of sex hormones, only provided genetic instruments for estrogen in men, but not for estrogen in women.^19^ We have explained this future work in the Discussion as follows.

"Here, we present a hypothesis driven study examining the role of testosterone in mediating the effect of specifically statins in IHD, particularly in men. Future work could encompass a comprehensive sex-specific multivariable MR to confirm the role of sex hormones and sex hormone binding globulin in IHD as well as any mediation of their effects by key lipids, such as LDL-cholesterol or apoB. This work would be facilitated by the development of published genetic instruments for estrogen in women.
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